MRFF – Emerging Priorities and Consumer Driven Research Initiative – 2026 Post-Acute Sequelae of COVID-19

Who can apply

The funder does not publish a structured list of eligible applicant types for this program. The eligibility criteria in the guidelines on the official page are the ones that count.

What the program funds

The objective of this grant opportunity (GO) is to provide grants of financial assistance to support medical research and medical innovation projects that: Stream 1 : ( Incubator ): investigate biological pathways and mechanistic drivers of PASC subtypes to optimise intervention design and improve clinical outcomes Stream 2 ( Incubator ): conduct novel pre-clinical and/or early-phase clinical research to improve the understanding of PASC subtypes

That description is National Health and Medical Research Council (NHMRC)'s own wording, reproduced from the official listing under CC BY 4.0 (Australian Government default open licence). Our plain-English summaries are being written program by program and this one has not been done yet.

What it is for

This program is categorised under the following purposes. Each one that has a page of its own links to every other Australian grant we track for the same purpose.

• Research and development

How to apply

Applications for MRFF – Emerging Priorities and Consumer Driven Research Initiative – 2026 Post-Acute Sequelae of COVID-19 are made through National Health and Medical Research Council (NHMRC), not through GrantWindow. We do not take applications, charge a fee or act as an intermediary, and any site that offers to apply on your behalf for a government grant is worth a very careful look.

Apply for MRFF – Emerging Priorities and Consumer Driven Research Initiative – 2026 Post-Acute Sequelae of COVID-19 on the official site

Applications close in September 2026. Government grant portals are busiest on the final day and several of them close on the stroke of the deadline, so the practical advice is to submit a day early.